NCT03414684: Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

NCT03414684
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms- see trial for details
https://ClinicalTrials.gov/show/NCT03414684

Comments are closed.

Up ↑